Mesoblast MEOBF Stock
Mesoblast Price Chart
Mesoblast MEOBF Financial and Trading Overview
| Mesoblast stock price | 1.9 USD |
| Previous Close | 1.9 USD |
| Open | 1.9 USD |
| Bid | 1.1 USD x 220000 |
| Ask | 1.9 USD x 110000 |
| Day's Range | 1.9 - 1.9 USD |
| 52 Week Range | 1.3 - 2.59 USD |
| Volume | 1 USD |
| Avg. Volume | 16.18K USD |
| Market Cap | 2.47B USD |
| Beta (5Y Monthly) | 0.822 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.04 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
MEOBF Valuation Measures
| Enterprise Value | 2.5B USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 0.14 |
| Price/Sales (ttm) | 20.517609 |
| Price/Book (mrq) | 4.3378997 |
| Enterprise Value/Revenue | 20.757 |
| Enterprise Value/EBITDA | -55.959 |
Trading Information
Mesoblast Stock Price History
| Beta (5Y Monthly) | 0.822 |
| 52-Week Change | 31.03% |
| S&P500 52-Week Change | 15.74% |
| 52 Week High | 2.59 USD |
| 52 Week Low | 1.3 USD |
| 50-Day Moving Average | 1.76 USD |
| 200-Day Moving Average | 1.65 USD |
MEOBF Share Statistics
| Avg. Volume (3 month) | 16.18K USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 1.3B |
| Float | 844.26M |
| Short Ratio | N/A |
| % Held by Insiders | 36.27% |
| % Held by Institutions | 17.21% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | -47.81% |
| Operating Margin (ttm) | -33.27% |
| Gross Margin | 80.01% |
| EBITDA Margin | -37.094% |
Management Effectiveness
| Return on Assets (ttm) | -4.11% |
| Return on Equity (ttm) | -9.86% |
Income Statement
| Revenue (ttm) | 120.25M USD |
| Revenue Per Share (ttm) | 0.09 USD |
| Quarterly Revenue Growth (yoy) | 390.69% |
| Gross Profit (ttm) | 96.22M USD |
| EBITDA | -44605000 USD |
| Net Income Avi to Common (ttm) | -57500000 USD |
| Diluted EPS (ttm) | -0.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 102.91M USD |
| Total Cash Per Share (mrq) | 0.08 USD |
| Total Debt (mrq) | 127.33M USD |
| Total Debt/Equity (mrq) | 22.4 USD |
| Current Ratio (mrq) | 2.435 |
| Book Value Per Share (mrq) | 0.438 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -43830000 USD |
| Levered Free Cash Flow (ttm) | -51976248 USD |
Profile of Mesoblast
| Country | United States |
| State | VIC |
| City | Melbourne |
| Address | 55 Collins Street |
| ZIP | 3000 |
| Phone | 61 3 9639 6036 |
| Website | https://www.mesoblast.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 108 |
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Q&A For Mesoblast Stock
What is a current MEOBF stock price?
Mesoblast MEOBF stock price today per share is 1.9 USD.
How to purchase Mesoblast stock?
You can buy MEOBF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mesoblast?
The stock symbol or ticker of Mesoblast is MEOBF.
Which industry does the Mesoblast company belong to?
The Mesoblast industry is Biotechnology.
How many shares does Mesoblast have in circulation?
The max supply of Mesoblast shares is 1.3B.
What is Mesoblast Price to Earnings Ratio (PE Ratio)?
Mesoblast PE Ratio is now.
What was Mesoblast earnings per share over the trailing 12 months (TTM)?
Mesoblast EPS is -0.04 USD over the trailing 12 months.
Which sector does the Mesoblast company belong to?
The Mesoblast sector is Healthcare.
